Fund moves

Medtronic (MDT): Manning & Napier Advisors LLC reduced its stake -22K shares

Manning & Napier Advisors LLC reduced its stake in Medtronic, per its Q1 2025 13F.

267K
Shares reported · -22K vs prior quarter
0.30%
Disclosed portfolio weight
$24M
Reported value
Holdings as of
Mar 31, 2025
Filed
Apr 22, 2025

What stands out in this filing

  • 289,117 shares in Q4 2024, 267,450 now (−7.5% in share count).
  • Reported at $24M, 0.30% of the portfolio value in this 13F filing.
  • 72 other tracked managers reported the same kind of change for Q1 2025.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 25, 2025CongressDisclosed purchase of MDT — reported range $1,001 - $15,000
  2. Mar 4, 2025CongressDisclosed purchase of MDT — reported range $1,001 - $15,000
  3. Mar 20, 2025CongressDisclosed sale of MDT — reported range $1,001 - $15,000
  4. Mar 24, 2025CongressDisclosed sale of MDT — reported range $50,001 - $100,000
  5. Apr 8, 2025CongressDisclosed sale of MDT — reported range $1,001 - $15,000

What came next

  1. May 8, 2025CongressDisclosed sale of MDT — reported range $15,001 - $50,000
  2. May 15, 2025CongressDisclosed purchase of MDT — reported range $1,001 - $15,000
  3. Jun 13, 2025FDAFDA device clearance: Medtronic Stedi Extra Support Guidewire
  4. Jun 16, 2025FDARecall: InPen App, CFN: MMT-8060 (iOS Users) and MMT-8061 (Android Users)
  5. Jun 17, 2025FDARecall: Medtronic SmartLink Software loaded on SmartSync Patient Connector, Model Number 24967 with the following software components: 1. Azure Astra application, Soft…
  6. Jun 17, 2025FDARecall: Medtronic SmartLink software loaded on CareLink SmartSync Device Manager, Model Number 24967A with the following software components: 1. Azure Astra applicatio…
  7. Jun 18, 2025FDARecall: Medtronic CareLink SmartSync Patient Connector, Model Number 24967 with the following software components: 1. Cobalt Crome application, Software Model Number D…
  8. Jun 18, 2025FDARecall: Medtronic CareLink SmartSync Device Manager, Model Number 24967A with the following software components: 1. Cobalt Crome application, Software Model Number D00…
  9. Jun 20, 2025FDAFDA device clearance: MC2™ Two-Stage Venous Cannula; MC2X™ Three-Stage Venous Cannula
  10. Jun 23, 2025FDARecall: Covidien Nellcor Bedside SpO2 Patient Monitoring System: REF: PM100N, 10005941, DLPM100N, DL10005941, DSPM100N, 10005941-SG, DS10005941, 10005941J, 10005941JP,…
  11. Jun 26, 2025FDAFDA device clearance: The Rialto™ SI Fusion System
  12. Jul 1, 2025FDAFDA device clearance: MiniMed 780G insulin pump
  13. Jul 17, 2025FDARecall: IPC Powerease System REF 2300000 UDI-DI: 00613994448705 00643169406834. The IPC POWEREASE System is indicated for drilling, tapping, and driving screws and wor…
  14. Aug 6, 2025FDAFDA device approval: Simplera Sync Sensor, Guardian 4 Sensor
  15. Aug 6, 2025FDARecall: DLP Left Heart Vent Catheter Malleable body and vented connector, SUCTION 12110 LV VENT 10FR, Model Number 12110
  16. Aug 6, 2025FDARecall: DLP Left Heart Vent Catheter Malleable body and vented connector, SUCTION 12115 LV VENT 15FR, Model Number 12115
  17. Aug 6, 2025FDARecall: DLP Left Heart Vent Catheter Malleable body and vented connector, SUCTION 12113 LV VENT 13FR, Model Number 12113
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Medtronic

For Medtronic, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MDT page.

How this filing works

Explore the data

Common questions

What does this filing report about Medtronic (MDT) stock?

Manning & Napier Advisors LLC reduced its stake in Medtronic, per its Q1 2025 13F. Now 267K shares, $24M reported value, 0.30% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Mar 31, 2025. Filed: Apr 22, 2025.

What stands out in this filing?

289,117 shares in Q4 2024, 267,450 now (−7.5% in share count). Reported at $24M, 0.30% of the portfolio value in this 13F filing. 72 other tracked managers reported the same kind of change for Q1 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Medtronic recently?

For Medtronic, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the MDT page.

Does this mean MDT stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Medtronic

Everything OQRO holds on this company is on its MDT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data